Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (450)	2/11/2004 2:24:55 AM
From: tuck	Read Replies (1) of 625

This free full text article implicates TRAIL in hepatic disease. Unclear to me if this is a negative for CATG and HGSI or a red herring since their program deals with TRAIL receptor, although the agonistic activity of their mAB is meant to mimic TRAIL activity . It would appear that exogenous TRAIL does not cause apoptosis of hepatocytes, but endogenous TRAIL in the liver does, but . . . well, read it yourself: jci.org Thoughts? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next